Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VASA Pilot Study
NCT07456852Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of isosorbide mononitrate and diltiazem in vascular toxicity (4 arms), sponsored by Mayo Clinic. Primary endpoint: Change in reactive hyperemia index. Started Apr 2026; status: recruiting.
02
Drugs
isosorbide mononitratediltiazem
03
Conditions
vascular toxicity
Beyond the preview
Go deeper on NCT07456852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07456852.